A randomised, double blind, placebo controlled trial to evaluate the safety, tolerability and anti-parasitic immunity boosting activity of ruxolitinib when co-administered with artemether-lumefantrine in healthy volunteers with Plasmodium falciparum Induced Blood Stage Malaria
Latest Information Update: 12 Jul 2021
At a glance
- Drugs Artemether/lumefantrine (Primary) ; Ruxolitinib (Primary)
- Indications Falciparum malaria
- Focus Adverse reactions
- 12 Jul 2021 New trial record